Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 8:00 a.m. ET. CEO Kyle Gano and VP of Investor Relations Todd Tushla will represent the company at the event.

The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for approximately one month after the event. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various neurological conditions, including tardive dyskinesia, Huntington's disease chorea, and endometriosis.

SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45^th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference.

The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-canaccord-genuity-45th-annual-growth-conference-302523607.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences (NBIX) presenting at the Canaccord Genuity Conference?

Neurocrine Biosciences will present at the conference on Wednesday, August 13, 2025, at 8:00 a.m. ET.

Who will be presenting for Neurocrine Biosciences at the Canaccord conference?

Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the conference.

How can investors access Neurocrine Biosciences' Canaccord conference presentation?

Investors can access the live webcast through Neurocrine Biosciences' website under the Investors section at www.neurocrine.com. A replay will be available for approximately one month.

What are Neurocrine Biosciences' (NBIX) main FDA-approved treatments?

NBIX has FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids (the latter two in collaboration with AbbVie).